Semaglutide: Need for caution | Photo Credit: th-online Administrator After the semaglutide molecule, used to treat type 2 diabetes and/or weight loss, went off patent last Friday, a flood of branded generics entered the market. The reaction has ranged from euphoria to alarm, as these generic versions are selling at 50-80 per cent lower than the price for the hitherto patented brands, Ozempic and Wegovy. In other words, the monthly cost of these generics is set to drop from ₹12,000 to ₹3,000 or...
Editorial. Weighty matter
Sourced from Hindu Business Line
Comments (0)
Log in to join the conversation.
No comments yet. Be the first to comment!
Related News
'Sir, yeh memes band nahi hone chahiye': Raghav Chadha joins meme fest on his Parliament speeches
The 37-year-old Rajya Sabha MP from Punjab has been actively raising a range of everyday issues during the ongoing Budge...
Housing sales in Jan-Mar dip 7% from December quarter due to West Asia conflict, up 9% annually: Anarock
Sales increased to 1,01,675 units during the current quarter from 93,280 units in the year-ago period
30 Days of West Asia conflict: India ups LPG output, focuses on PNG as imports concerns persist
While India has “sufficient” stocks of crude oil, natural gas, petrol, diesel and jet fuel, it faces supply risk with re...
‘Humanitarian catastrophe’: While the world is focused on the war in Iran, something much worse is unfolding in Lebanon
Following the US-Israeli Operation Epic Fury against Iran, Israel's ground invasion of Lebanon has led to significant ci...
Jaishankar raises concerns about food, fuel, fertilizer shortages at G-7 meet
External Affairs Minister stresses importance of resilient trade corridors, such as the IMEC, especially amidst uncertai...
More from Hindu Business Line
30 Days of West Asia conflict: India ups LPG output, focuses on PNG as imports concerns persist
Redefining identity and access
Why the reduction in SED